Publications by authors named "Lesli A Lavery"

2 Publications

  • Page 1 of 1

Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses.

Leuk Lymphoma 2019 09 8;60(9):2295-2298. Epub 2019 Mar 8.

Department of Hematologic Oncology and Blood Disorders, Atrium Health, Levine Cancer Institute , Charlotte , NC , USA.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1576871DOI Listing
September 2019

Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma.

J Adv Pract Oncol 2018 Mar 1;9(2):235-240. Epub 2018 Mar 1.

Levine Cancer Institute, Atrium Health, Rock Hill, South Carolina; and Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.

Olaratumab is a monoclonal antibody that recently received accelerated approval for the treatment of advanced soft-tissue sarcomas in combination with doxorubicin for a histologic subtype in which anthracycline-containing regimens is appropriate and disease is not amenable to curative surgery or radiotherapy. It inhibits platelet-derived growth factor receptor alpha, leading to the inhibition of tumor cell proliferation, angiogenesis, and metastasis. In a phase II clinical trial, olaratumab in combination with doxorubicin met its predefined primary endpoint of improving progression-free survival and secondary endpoint of overall survival compared to doxorubicin monotherapy in patients with advanced soft-tissue sarcoma. Common adverse events associated with the combination of olaratumab and doxorubicin include nausea, mucositis, neutropenia, and infusion-related reactions.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303001PMC
March 2018